Company: BLLN
Filing Date: 2025-10-17
Form Type: S-1/A
Source: 0001193125-25-242632
Chunk: 14

Company: BillionToOne, Inc.
Filing Date: 2025-10-17
Form: S-1/A
Chunk 14
---
 to dramatic differences in end-point PCR abundances of different sequences

QCT: Quantitative Counting Templates—BillionToOne’s patented synthetic DNA fragments that are the foundation of the smNGS platform. See
“Business—Our Technology—The components of our platform—Quantitative Counting Templates (QCTs)”

Sample accessioning:The
process in a laboratory where incoming specimens are received, logged, labeled, and assigned unique identifiers as soon as they arrive

SCD: Sickle cell
disease—A hereditary red blood cell disorder that can be detected by UNITY tests

sgNIPT: Single-gene
non-invasive prenatal testing—A type of test pioneered by BillionToOne that can detect single-gene disorders without paternal sample. See “Business—Our Product Portfolio” for a
description of how sgNIPT is used in our products

SMA: Spinal muscular atrophy—A genetic disorder that can be detected by UNITY tests

smNGS: Single-molecule next-generation sequencing—BillionToOne’s platform technology that enables detection and quantification of blood-based genetic
targets with single molecule sensitivity. See “Business—Our Technology—Breakthrough performance capabilities”

SNV: Single nucleotide
variant—A variation in a gene’s sequence that Northstar Select can detect

TMS: Tumor Methylation Score—Northstar Response’s metric
that measures the quantity of cancer-specific DNA methylation in blood for monitoring response to a cancer therapy

vi

Prospectus Summary

Prospectus summary This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our Class A common stock, you should carefully read this entire prospectus, including our financial statements and the related notes included elsewhere in this prospectus and the information set forth under the sections titled “Risk factors,” “Special note regarding forward-looking statements,” and “Management’s discussion and analysis of financial condition and results of operations.” Unless the context otherwise requires the terms “BillionToOne,” “company,” “our,” “us” and “we” in this prospectus to refer to BillionToOne, Inc. Overview BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection –